Affiliation:
1. Filatov City Clinical Hospital No.15 of the Moscow Department of Health; Pirogov Russian National Research Medical University of the Ministry of Health of Russia
2. Filatov City Clinical Hospital No.15 of the Moscow Department of Health
Abstract
The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of direct selective oral anticoagulants represented by the thrombin inhibitor dabigatran and the factor Xa inhibitor group including apixaban, edoxaban and rivaroxaban. This article provides a thorough introduction of apixaban with an evidence base allowing to consider it a priority anticoagulant, which may be reasonably administered to the majority of patients with pulmonary thromboembolism from the first hours of the disease to many years of secondary prevention.